Patents Issued in June 22, 2017
  • BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170174697
    Abstract: Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventor: Yun LONG
  • METHOD FOR THE SYNTHESIS OF PRIMARY ISOHEXIDE AMINES
    Publication number: 20170174698
    Abstract: A method for synthesizing a primary amine, having the steps of: a) providing at least one dianhydrohexitol, and b) aminating the dianhydrohexitol by reacting same with ammonia, the amination being performed by heterogeneous catalysis using a hydrogenation catalyst in the presence of hydrogen.
    Type: Application
    Filed: July 18, 2014
    Publication date: June 22, 2017
    Applicant: RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHLULE (RWTH) AACHEN
    Inventors: Marcus ROSE, Regina PALKOVITS, Rebecca ENGEL, Alireza HAJI BEGLI, Christine KROENER
  • COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
    Publication number: 20170174699
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • Biotin Derivatives
    Publication number: 20170174700
    Abstract: Biotin derivatives, methods of using the biotin derivatives and kits comprising the biotin derivatives.
    Type: Application
    Filed: December 27, 2016
    Publication date: June 22, 2017
    Inventors: Lai-Qiang YING, Bruce BRANCHAUD, Yu-Zhong ZHANG, Stephen YUE
  • CYCLIC CARBONATE MONOMER CONTAINING DOUBLE-SULFUR FIVE-MEMBERED RING FUNCTIONAL GROUP, AND PREPARATION METHOD THEREOF
    Publication number: 20170174701
    Abstract: Disclosed are a cyclic carbonate monomer containing a double-sulfur five-membered ring functional group, and preparation method thereof. The cyclic carbonate monomer can be simply and efficiently synthesized without protection and deprotection processes. The cyclic carbonate monomer of the present invention can be utilized to obtain polycarbonate having a controllable molecular weight and molecular weight distribution via ring opening polymerization, and has biodegradability and reduction-sensitive reversible crosslinking properties. The present invention can be used in a carrier having controllably released drug, a biological tissue scaffold or a biochip.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 22, 2017
    Inventors: Fenghua Meng, Yan Zou, Zhiyuan Zhong
  • BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER
    Publication number: 20170174702
    Abstract: Provided is a novel compound having bromodomain and extra terminal domain (BET) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.
    Type: Application
    Filed: April 8, 2015
    Publication date: June 22, 2017
    Applicant: KAINOS MEDICINE, INC.
    Inventors: Su-Sung OH, Minjeong CHOI
  • QUINOLINE DERIVATIVES AS SMO INHIBITORS
    Publication number: 20170174703
    Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.
    Type: Application
    Filed: March 16, 2015
    Publication date: June 22, 2017
    Inventors: Hao WU, Chaofeng LONG, Jun LIN, Xiaoxin CHEN, Yunhui LI, Zhuowei LIU, Changqing WEI, Lijuan CHEN, Shuhui CHEN
  • QUINOXALINE COMPOUNDS AND USES THEREOF
    Publication number: 20170174704
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE
    Publication number: 20170174705
    Abstract: A condensed cyclic compound represented by Formula (1): wherein, in Formula (1), groups and variables are the same as described in the specification.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 22, 2017
    Inventors: Fumiaki KATO, Satoshi INAYAMA, Norihito ISHII, Katsunori SHIBATA, Mitsunori ITO
  • SPIRO-OXAZINES, INDOLINONES AND PREPARATION THEREOF
    Publication number: 20170174706
    Abstract: The present invention relates to novel spiro-oxazine analogues of Formula-I and Indolinone compounds of Formula-II or positional isomers, or stereoisomers, or derivatives, or pharmaceutically acceptable salt thereof. Formula-I Formula-II Further the invention provides transition-metal free multicomponent reaction (MCR) process for the preparation of said compounds of Formula-I and II using aryne precursor, N-substituted isatin and N-heteroaromatic compound as the nucleophile, under mild condition leading to formation of desired complex of spiro-oxazine analogues (I) and indolinone analogues (II) in high yield and selectivity.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Biju Akkattu Thankappan, Anup Bhunia, Tony Roy
  • HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES
    Publication number: 20170174707
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q is and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Application
    Filed: September 9, 2014
    Publication date: June 22, 2017
    Inventors: David Alan Clark, Breena Gloriana Fraga, Wenming Zhang
  • PENTACYCLIC PYRIDOINDOLOBENZO[b,e]DIAZEPINES AND THIAZEPINES FOR TREATING CNS DISORDERS
    Publication number: 20170174708
    Abstract: The present invention discloses pyridoinolobenzo[b,e]diazepine and thiazepine derivatives of Formula 1, wherein X is NR10, S, S(O), or S(O)2. Y is a single bond or no bond. A and B are independently (CH2)m and (CH2)n respectively; and the subscripts ‘m’ and ‘n’ independently vary from 1 to 4. R1 to R9 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.
    Type: Application
    Filed: February 6, 2017
    Publication date: June 22, 2017
    Applicant: Daya Drug Discoveries, Inc.
    Inventor: Parthasarathi Rajagopalan
  • TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS
    Publication number: 20170174709
    Abstract: The present invention provides a tricyclic compound represented by general formula (I), a pharmaceutical salt thereof, or a stereoisomer thereof exhibits excellent antibacterial activity against Gram-negative bacteria resistant bacteria thereof, and also being excellent in terms of safety. Furthermore, the present invention provides production processes, pharmaceutical compositions comprising a tricyclic compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof as an active ingredient and use thereof as a pharmaceutical agent. The compounds of the present invention are useful for the treatment and/or prevention of disease such as complicated urinary tract infections (cUTIs), nosocomial pneumonia, intra-abdominal infections (IAIs) or bacteremia.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 22, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ajay Soni, Aditi Agarwal, Sangram Shesharao Deshmukh, Kedar Padmakar Purnapatre, Shinji Marumoto
  • COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS
    Publication number: 20170174710
    Abstract: Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).
    Type: Application
    Filed: December 2, 2016
    Publication date: June 22, 2017
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Zhili Xin, Lei Zhang
  • ACID GENERATOR AND COMPOSITION
    Publication number: 20170174711
    Abstract: Acid generators and compositions are disclosed. Such acid generators and compositions are applicable to functional materials such as adhesives, sealant or antireflection coating (ARC).
    Type: Application
    Filed: December 16, 2016
    Publication date: June 22, 2017
    Applicant: TOYO GOSEI CO., LTD.
    Inventors: Takashi MIYAZAWA, Yuki TOMA
  • Silicon-containing azodicarboxamides, their preparation and use
    Publication number: 20170174712
    Abstract: A silicon-containing azodicarboxamide is obtainable by reacting an azodicarboxy compound with an aminosilane. The silicon-containing azodicarboxamides are suitable for use in cable sheathing, hoses, drive belts, conveyor belts, roll coverings, footwear soles, ring seals and damping elements.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 22, 2017
    Applicant: EVOINIK DEGUSSA GmbH
    Inventors: Karsten Korth, Julia Keck, Sascha Erhardt, Jaroslaw Monkiewicz, Christian Springer, Elisabeth Bauer
  • TANK-BINDING KINASE INHIBITOR COMPOUNDS
    Publication number: 20170174713
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: December 15, 2016
    Publication date: June 22, 2017
    Inventors: Zhimin Du, David Dornan, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Devan Naduthambi, Barton W. Phillips, Susanna Y. Stinson, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins
  • PROCESS OF PREPARING CYCLIC PHOSPHONATE ESTER, CYCLIC PHOSPHONATE ESTER PREPARED THEREFROM AND INDUSTRIAL APPLICATIONS CONTAINING THE SAME
    Publication number: 20170174714
    Abstract: There is provided herein a process for preparing cyclic phosphonate ester comprising reacting a glycol with at least one of phosphonic acid and phosphinic acid in the presence of a solvent. There is also provided a flame retardant comprising the cyclic phosphonate ester and industrial applications containing a flame retardant effective amount of the cyclic phosphonate ester.
    Type: Application
    Filed: March 12, 2015
    Publication date: June 22, 2017
    Inventors: Jean-luc Montchamp, Lucie Prost
  • BIDENTATE DIPHOSPHORAMIDITES WITH A PIPERAZINE GROUP AS LIGANDS FOR HYDROFORMYLATION
    Publication number: 20170174715
    Abstract: The invention relates to Rh, Ru, Co and Ir complexes comprising bidentate diphosphoramidites as ligands and to the use thereof as catalysts for the hydroformylation of olefins. The invention also relates to a process for preparing an aldehyde from an olefin using the complexes or ligands mentioned.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 22, 2017
    Applicant: EVONIK DEGUSSA GMBH
    Inventors: Katrin Marie DYBALLA, Robert FRANKE, Dirk FRIDAG, Dieter HESS, Frank GEILEN, Galina Morales TORRES, Detlef SELENT, Armin BÖRNER
  • FUMARATE-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
    Publication number: 20170174716
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto MOTTERLINI, Roberta FORESTI, Thierry MARTENS, Michael RIVARD
  • METHOD OF SEPARATING BETANIN FROM RED QUINOA BY SUPERCRITICAL FLUID FRACTIONATION
    Publication number: 20170174717
    Abstract: The present invention relates to a method of separating betanin from red quinoa by supercritical fluid fractionation, including: mixing an extract of red quinoa with an ethanol/water mixture to obtain a mixture of red quinoa/ethanol/water; and separating betanin from the mixture of red quinoa/ethanol/water by supercritical fluid fractionation, which operates under a pressure between 2300 to 4400 psi at a temperature between 35 to 65° C. for a period of time between 15 to 90 minutes.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 22, 2017
    Inventors: Ho-Hsien Chen, Chen-Hsing Yu, Nyvonne Tiqu Gina Nelma
  • SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS
    Publication number: 20170174718
    Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 22, 2017
    Inventors: Jason Gustaf LEWIS, Michael Robert LEADBETTER, Jeremy CALDWELL, Dean DRAGOLI, Noah BELL, Jeffrey W. JACOBS, Patricia FINN, Rakesh JAIN, Tao CHEN, Matthew SIEGEL
  • PROCESS FOR THE PURIFICATION OF FLUTICASONE PROPIONATE USING A KETONE SOLVENT AND WATER AS ANTI-SOLVENT
    Publication number: 20170174719
    Abstract: The present disclosure relates to an improved process for the purification of fluticasone propionate by: a) dissolving fluticasone propionate in a ketone solvent to produce a mixture, b) heating the mixture slowly for 1-2 hours to get a clear solution, c) adding water to the step (b) solution at 50-60° C., d) cooling to ?5° C. to 10° C., and e) isolating fluticasone propionate.
    Type: Application
    Filed: February 5, 2015
    Publication date: June 22, 2017
    Applicant: Mylan Laboratories Ltd.
    Inventors: Sakharam Jadhav, Chandersingh Bohara, Ghanshyam Wagh, Vinayak Govind Gore, Maheshkumar Gadakar
  • CATIONIC STEROIDAL ANTIMICROBIAL SALTS
    Publication number: 20170174720
    Abstract: Disclosed herein are acid addition salts of cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous salt forms are identified, such as 1,5-naphthalenedisulfonic acid addition salts and sulfate addition salts. The acid addition salts may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering acid addition salts of CSAs.
    Type: Application
    Filed: April 22, 2016
    Publication date: June 22, 2017
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Saurabh Shashikant Chitre, Kunal Arvind Varia, Hayley Ann Reece, Thomas E. Jacks, Ross A. Miller, Jared Lynn Randall
  • BUFFER SYSTEM FOR PROTEIN PURIFICATION
    Publication number: 20170174721
    Abstract: A method for purifying a protein using a simplified, sodium chloride-free buffer system that consists of two components (acid and base pairs) for appropriate solution pH control; and a third component for ionic strength control, where the third component is the sodium salt conjugate base.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Inventors: Kent E. GOKLEN, Eric J. SUDA, Antonio Raul UBIERA
  • LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT
    Publication number: 20170174722
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Applicant: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20170174723
    Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.
    Type: Application
    Filed: October 13, 2016
    Publication date: June 22, 2017
    Applicant: The Regents of the University of California
    Inventors: Sven H. Hausner, Julie L. Sutcliffe
  • BIOLOGICALLY ACTIVE PEPTIDES
    Publication number: 20170174724
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • PROCESSES FOR THE PREPARATION OF OXYTOCIN ANALOGUES
    Publication number: 20170174725
    Abstract: Provided herein is a process for the preparation of oxytocin receptor agonists that have the potential to be used for the treatment of neurological disorders.
    Type: Application
    Filed: February 7, 2017
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Anton Cueni, Kurt Puentener, Junichi Shiina
  • STABILIZED PEPTOID-PEPTIDE HYBRIDS AND USES THEREOF
    Publication number: 20170174726
    Abstract: The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.
    Type: Application
    Filed: March 31, 2015
    Publication date: June 22, 2017
    Inventors: MARK MCLAUGHLIN, AMOD A. SARNAIK
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20170174727
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: December 29, 2014
    Publication date: June 22, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: MICHAEL DOCKAL, RUDOLF HARTMANN, FRIEDRICH SCHEIFLINGER, FRANK OSTERKAMP, THOMAS POLAKOWSKI, ULRICH REINEKE
  • Soluble Forms of Hendra and Nipah Virus G Glycoprotein
    Publication number: 20170174728
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Application
    Filed: December 30, 2016
    Publication date: June 22, 2017
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20170174729
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides.
    Type: Application
    Filed: August 9, 2016
    Publication date: June 22, 2017
    Inventors: Tapas K. Das Gupta, Craig W. Beattie
  • BLUE LIGHT-ACTIVATED ION CHANNEL MOLECULES AND USES THEREOF
    Publication number: 20170174730
    Abstract: The invention, in some aspects relates to light-activated ion channel polypeptides and encoding nucleic acids and also relates in part to compositions comprising light-activated ion channel polypeptides and methods using light-activated ion channel polypeptides to alter cell activity and function.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Applicants: Massachusetts Institute of Technology, The Governors of the University of Alberta, President and Fellows of Harvard College
    Inventors: Nathan Klapoetke, Edward Boyden, Yongku Cho, Brian Y. Chow, Gane K.S. Wong, Adam E. Cohen, Daniel R. Hochbaum
  • TOXIC PEPTIDE PRODUCTION, PEPTIDE EXPRESSION IN PLANTS AND COMBINATIONS OF CYSTEINE RICH PEPTIDES
    Publication number: 20170174731
    Abstract: New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.
    Type: Application
    Filed: December 23, 2016
    Publication date: June 22, 2017
    Applicant: Vestaron Corporation
    Inventors: Robert M. Kennedy, William Tedford, Christopher Hendrickson, Robert Venable, Catherine Foune, John McIntyre, Alvar Carlson, Lin Bao
  • NANOBODY-FLOURESCENT PROTEIN FUSION
    Publication number: 20170174732
    Abstract: We describe the rational structure-based design of monomeric and dimeric forms of a nanobody-enhanced GFP (termed vsfGFP) that demonstrates ˜1.3-fold higher brightness than sfGFP in a monomeric form and ˜2.5-fold higher brightness in a dimeric form. These new vsfGFP variants demonstrate high stability and brightness in both bacterial and eukaryotic cells and are thus ideal for in vivo imaging applications. The combination of higher brightness, facile folding, stable expression, and tunable dimerization makes them ideal partners in essentially all in vitro applications already described for fluorescent proteins, including antibody fusion-based molecular probes, for which the higher brightness and tunable dimerization provide distinct advantages. Furthermore, the vsfGFP variants retain folding properties of sfGFP that enable bright fluorescence in oxidizing environments such as the bacterial periplasm.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 22, 2017
    Inventors: Swaine Chen, Majid Eshaghi
  • CHAGASIN-BASED SCAFFOLD COMPOSITIONS, METHODS, AND USES
    Publication number: 20170174733
    Abstract: Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).
    Type: Application
    Filed: June 19, 2015
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Robert A. LAZARUS, Henry R. MAUN
  • DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide
    Publication number: 20170174734
    Abstract: The present invention provides compositions and methods of treating cancer by inducing the cellular differentiation activity of angiocidin.
    Type: Application
    Filed: March 12, 2015
    Publication date: June 22, 2017
    Inventor: George P. Tuszynski
  • COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES
    Publication number: 20170174735
    Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.
    Type: Application
    Filed: March 12, 2015
    Publication date: June 22, 2017
    Applicant: ALFACYTE LTD
    Inventor: William STIMSON
  • LONG-ACTING RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE-FC FUSION PROTEIN
    Publication number: 20170174736
    Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fe variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
    Type: Application
    Filed: August 22, 2014
    Publication date: June 22, 2017
    Inventors: Yongmin Hou, Qiang Li, Maobo Wu, Sha Liao, Yujie Zhang, Zhenqi Xu
  • CHROMATOGRAPHY PROCESS FOR PURIFICATION OF INSULIN AND INSULIN ANALOGS
    Publication number: 20170174737
    Abstract: A process is described for purifying insulin and insulin analogs that comprises use of two or more orthogonal chromatographic purification steps in tandem following enzymatic digestion of the propeptide-insulin precursor to remove specific product impurities, improve process consistency, and increase process redundancy in the purification of the insulin or insulin analog, e.g., insulin lispro.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 22, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Douglas S. Watson, Allison D. Ortigosa, Michael A. Rauscher, Kathryn M. Story
  • ALPHA- AND GAMMA-MSH ANALOGUES
    Publication number: 20170174738
    Abstract: The present invention provides peptide analogues of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
    Type: Application
    Filed: October 10, 2016
    Publication date: June 22, 2017
    Inventor: Thomas Boesen
  • Protein-Based Molecular Temperature Switch
    Publication number: 20170174739
    Abstract: A region of the TRPM8 protein that functions as a temperature switch (FIG. 1) has been identified, and can be expressed, purified and applied in combination with other proteins. The function of the switch is maintained even when the region or domain is isolated from the entire protein. As the protein domain is a temperature switch, it can be used to control other proteins and signaling pathways in vitro and in vivo; and 2) TRPM8 is a therapeutic target that is being pursued primarily for intervention in pain (neuropathic and inflammatory) and cancer.
    Type: Application
    Filed: February 11, 2015
    Publication date: June 22, 2017
    Inventors: Wade Van Horn, Nicholas Sisco, Parthasarathi Rath
  • KV2.1 CHANNEL-DERIVED PEPTIDES AND METHODS OF USE
    Publication number: 20170174740
    Abstract: Peptides capable of interfering with the Kv2.1-mediated apoptotic K+ current surge that leads to neuronal cell death are described. The disclosed peptides are derived from the C-terminal region of Kv2.1, which mediates binding to the SNARE protein syntaxin. Disruption of Kv2.1 binding to syntaxin inhibits the apoptotic K+ current surge that leads to neuronal cell death. The present disclosure provides methods of inhibiting binding of Kv2.1 to syntaxin in a cell (in vitro or in vivo), such as for neuroprotection following cerebral ischemia, stroke, or traumatic brain injury, or during the course of a neurodegenerative disease, or any other condition associated with neuronal cell death.
    Type: Application
    Filed: March 17, 2015
    Publication date: June 22, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Elias Aizenman, Meghan McCord
  • COMBINATORIAL GAMMA 9 DELTA 2 T CELL RECEPTOR CHAIN EXCHANGE
    Publication number: 20170174741
    Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain MICR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 22, 2017
    Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20170174742
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: April 24, 2015
    Publication date: June 22, 2017
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16
    Publication number: 20170174743
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Application
    Filed: March 27, 2015
    Publication date: June 22, 2017
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Li
  • NEW METHOD FOR TREATING MELANOMA
    Publication number: 20170174744
    Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
    Type: Application
    Filed: May 12, 2015
    Publication date: June 22, 2017
    Inventors: Bruno SEGUI, Nathalie ANDRIEU-ABADIE, Thierry LEVADE, Celine COLACIOS VIATGE, Philippe ROCHAIX, Florie BERTRAND, Herve BENOIST, Julia ROCHOTTE
  • MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS
    Publication number: 20170174745
    Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
    Type: Application
    Filed: November 17, 2016
    Publication date: June 22, 2017
    Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'ANGELO, David Kai Yuen POON
  • Recombinant Bacterium and Uses Thereof
    Publication number: 20170174746
    Abstract: The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type Ill secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided.
    Type: Application
    Filed: December 5, 2016
    Publication date: June 22, 2017
    Applicant: National Research Council of Canada
    Inventors: Subash Sad, Lakshmi Krishnan, Fanny Tzelepis, Valeria Alcon, Kevin G. Young